<DOC>
	<DOCNO>NCT01613079</DOCNO>
	<brief_summary>Evaluation oral T2 ( chloroform/methanol extract Tripterygium wilfordii Hook F ) treatment RA patient clinical efficacy safety.Open-labeled , randomize , prospective multi-center clinical trial . Observation period 24 week .</brief_summary>
	<brief_title>Efficacy Safety Tripterygium Wilfordii Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age 1865 year inform consent Diagnosed rheumatoid arthritis determine meeting 2010 ACR/EULAR classification criterion rheumatoid arthritis least 6 week Swollen joint ( SJC ) ≥3 tender joint count ( TJC ) ≥5 ESR &gt; 28 mm/hr Creactive protein &gt; 20 mg/L Pregnant , lactate fertility requirement Previous treat methotrexate biologic DMARD . Active chronic infection , include HIV , HCV , HBV , tuberculosis Patient cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tripterygium</keyword>
</DOC>